Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Korea United Pharm's share price for the quarter that ended in Jun. 2026 was ₩17450. Korea United Pharm's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 14 Mil. Therefore, Korea United Pharm's market cap for the quarter that ended in Jun. 2026 was ₩252,013 Mil.
Korea United Pharm's quarterly market cap
increased
from Dec. 2025 (₩275,409 Mil) to Mar. 2026 (₩314,841 Mil) but then
declined
from Mar. 2026 (₩314,841 Mil) to Jun. 2026 (₩252,013 Mil).
Korea United Pharm's annual market cap
declined
from Dec. 2023 (₩394,794 Mil) to Dec. 2024 (₩267,887 Mil) but then
increased
from Dec. 2024 (₩267,887 Mil) to Dec. 2025 (₩275,409 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Korea United Pharm's Enterprise Value for Today is ₩94,954 Mil.
Korea United Pharm (XKRX:033270) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Korea United Pharm Market Cap Related Terms
Korea United Pharm Market Cap Historical Data
* Premium members only.
The historical data trend for Korea United Pharm's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Korea United Pharm's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korea United Pharm Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Korea United Pharm's Market Cap distribution charts can be found below:
* The bar in red indicates where Korea United Pharm's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Korea United Pharm's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korea United Pharm (XKRX:033270) has a Market Cap of ₩258,650 Mil as of Aug. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Korea United Pharm and its competitors. According to the industry distribution chart, Korea United Pharm ranks #541 out of 1021 companies in the Drug Manufacturers industry, placing it in the top 53%.
Is Korea United Pharm's Market Cap too high?
Korea United Pharm's current Market Cap is ₩258,650 Mil. Based on the distribution chart, Korea United Pharm ranks #541 out of 1021 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Korea United Pharm has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Korea United Pharm's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Korea United Pharm ranks #541 out of 1021 companies for Market Cap. This places Korea United Pharm in the lower half of its industry. The industry median Market Cap is 235.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 235.54, based on 1,021 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Korea United Pharm and its competitors. For the Drug Manufacturers industry, the median Market Cap is 235.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Korea United Pharm's current Market Cap is ₩258,650 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korea United Pharm stock overvalued right now?
Based on GuruFocus' analysis, Korea United Pharm (XKRX:033270) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩20,351.55, compared to a current price of ₩17,910.00 — trading 12% below its estimated fair value. The current Market Cap is ₩258,650 Mil. Korea United Pharm's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Korea United Pharm (XKRX:033270), the current Market Cap is ₩258,650 Mil as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Korea United Pharm (XKRX:033270) Overvalued in 2026?
Based on GuruFocus' analysis, Korea United Pharm stock appears to be undervalued.
The current stock price of ₩17,910.00 is trading 12% below its estimated GF Value™ of ₩20,351.55.
GuruFocus considers Korea United Pharm to be Modestly Undervalued.
Key valuation signals for XKRX:033270:
Market Cap: ₩258,650 Mil
GF Value™: ₩20,351.55 vs. price of ₩17,910.00 (12% below fair value)
No single metric tells the full story. See the XKRX:033270 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Korea United Pharm Inc is a South Korea based company engages in the manufacture and distribution of pharmaceuticals and healthcare products. It offers incrementally modified drug, anti-cancer, prescription, and OTC products.
91GF Score
Get the complete analysis for XKRX:033270
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:033270 has been successfully added to your 
